All News

The findings were derived from the multicenter, prospective, phase 3 STAMPEDE trial.

Christopher Weight, MD, MS, discusses the current state and directions of AI and prostate cancer.

“This shows that AI analysis of routine biopsies can detect subtle signs indicating clinically significant prostate cancer before it becomes obvious to a pathologist," says Carolina Wählby, PhD.

Gvili explains that many patients with pelvic floor dysfunction are young men (20–45 years old), though he also treats patients who have undergone radical prostatectomy.

Take a look through the novel agents that are set to further redefine the treatment landscape for high-risk BCG-unresponsive NMIBC.

Darolutamide plus ADT has also been approved in the US as well as in the European Union.

“We hope our findings reassure health professionals caring for postmenopausal women with a history of stroke,” says Kimia Ghias Haddadan, MD.

The presentations featured data on the drug candidate BOTRESO for BPH and LUTS, as well as on the prostate cancer prevention drug MCS-8.

Robert B. Den, MD, outlines the exploratory applications of the Alpha DaRT technology across the prostate and bladder cancer landscapes.

Concurrent use of an ARPI with [177Lu]Lu-PSMA-617 did not improve response rates nor overall survival in patients with ARPI-refractory mCRPC.

The approval of oral sulopenem was supported by data from the phase 3 SURE 1 (NCT03366207) and REASSURE (NCT05584657) trials.

The findings suggest that urolithiasis continues to pose a significant healthcare burden worldwide.

"We are lucky to be in the position to offer so many treatment options customized to address [patients'] needs and help them enjoy life," says Kevin C. Zorn, MD, FRCSC, FACS.

Patients who were Signatera positive and received treatment with atezolizumab had a statistically significant and clinically meaningful improvement in DFS and OS.

Singer reflects on how clinical trial design, patient selection, and biomarker research are driving more individualized therapy choices.

According to the authors, these data support the value of PSMA PET/CT in the pre-salvage radiotherapy selection process.

First Assist: GU Oncology Unpacked, hosted by Taylor Goodstein, MD, is the latest multimedia program from Urology Times.

The ARCHER trial is seeking to determine whether ultra-hypofractionated radiotherapy is non-inferior to hypofractionated radiotherapy in terms of bladder-intact event-free survival.

The agent is currently being evaluated in a phase 1/2 trial.

"Pediatric-type cancer diagnoses in adults are rare, and there are important differences in caring for children with genitourinary malignancies compared with adults," write the authors.

The ArteraAI test is now the first and only AI-powered tool to be authorized to prognosticate long-term outcomes in patients with localized prostate cancer.

The target action date for the application is December 11, 2025.

Canes describes the challenges of modern urology practice, from the deluge of portal messages to the variability in how clinicians deliver pre- and post-visit instructions

An interim analysis of the data showed that the trial met its primary end point of EFS, as well as the key secondary end points of OS and pCR rate.

This marks the first and only approval of a perioperative immunotherapy in this disease setting in Canada.

HIFU was shown to be an effective and tolerable treatment option for patients with intermediate-risk localized prostate cancer.

The target action date for the application is March 6, 2026.

In the phase 3 RC48-C016 study, disitamab vedotin plus toripalimab significantly improved PFS and OS vs chemotherapy.